Long-term survival of favorable-risk patients with metastatic renal cell carcinoma treated with second-line axitinib in a multicenter phase II study.

被引：0

作者：

Tsimafeyeu, Ilya ^{[1
]}

Borisov, Pavel S. ^{[2
]}

Semenov, Andrey ^{[3
]}

Leonenkov, Roman ^{[4
]}

Novikova, Olga ^{[5
]}

Gamayunov, Sergey ^{[6
]}

Mikhailova, Nadezhda ^{[7
]}

Bondarenko, Anastasia ^{[8
]}

Abdelgafur, Ahmed ^{[6
]}

机构：

[1] Kidney Canc Res Bur, Moscow, Russia

[2] City Clin Oncol Ctr, St Petersburg, Russia

[3] Ivanovo Canc Ctr, Ivanovo, Russia

[4] St Petersburg City Canc Ctr, St Petersburg, Russia

[5] Khabarovsk Reg Canc Ctr, Khabarovsk, Russia

[6] Republican Clin Oncol Ctr, Cheboksary, Russia

[7] Republican Clin Oncol Ctr, Kazan, Russia

[8] IM Sechenov First Moscow State Med Univ, Moscow, Russia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.332

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

332

引用

页数：2

共 50 条

[21] Choosing the Best Approach for Patients With Favorable-Risk Metastatic Renal Cell Carcinoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (04) : 204 - 207
[22] A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
Lin, Zhong-Zhe
Chen, Bang-Bin
Hung, Yi-Ping
Huang, Po-Hsiang
Shen, Ying-Chun
Shao, Yu-Yun
Hsu, Chih-Hung
Cheng, Ann-Lii
Lee, Rheun-Chuan
Chao, Yee
Hsu, Chiun
ONCOLOGIST, 2020, 25 (09): : E1280 - E1285
[23] Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Geczi, Lajos
Bodoky, Gyorgy
Rokszin, Gyorgy
Fabian, Ibolya
Torday, Laszlo
PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2201 - 2207
[24] Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
Lin, Dengqiang
Lai, Peng
Zhang, Wen
Lin, Jinglai
Wang, Hang
Hu, Xiaoyi
Guo, Jianming
FRONTIERS IN ONCOLOGY, 2023, 13
[25] Choosing the Best Approach for Patients With Favorable-Risk Metastatic Renal Cell Carcinoma Comment
Zhang, Tian
George, Daniel J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (04) : 207 - 207
[26] Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.
Atkins, Michael B.
Puzanov, Igor
Plimack, Elizabeth R.
Fishman, Mayer N.
McDermott, David F.
Cho, Daniel C.
Vaishampayan, Ulka N.
George, Saby
Tarazi, Jamal Christo
Duggan, William
Perini, Rodolfo F.
Fernandez, Kathrine C.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial
Motzer, R. J.
Rouge, T. de La Motte
Harzstark, A. L.
Michaelson, M. D.
Liu, G.
Gruenwald, V.
Ingrosso, A.
Tortorici, M. A.
Bycott, P. W.
Kim, S.
Rini, B. I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[28] Long-term Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Pulsed Dendritic Cells
Kraemer, Markus
Hauser, Stefan
Schmidt-Wolf, Ingo G. H.
ANTICANCER RESEARCH, 2010, 30 (06) : 2081 - 2086
[29] Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
Motzer, R. J.
Alyasova, A.
Ye, D.
Karpenko, A.
Li, H.
Alekseev, B.
Xie, L.
Kurteva, G.
Kowalyszyn, R.
Karyakin, O.
Neron, Y.
Cosgriff, T.
Collins, L.
Brechenmacher, T.
Lin, C.
Morgan, L.
Yang, L.
ANNALS OF ONCOLOGY, 2016, 27 (03) : 441 - 448
[30] Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic osteosarcomas: A multicenter phase II study.
Bin Bui, N.
Egerer, G.
Ferrari, S.
Comandone, A.
Cioffi, A.
Rassam, H.
Michel, A.
Ameryckx, S.
Weitckus, S.
Duffaud, F.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →